Uniphar appoints industry leader, Isaac Batley, as Global Head of Scientific Communications
January 16, 2025 | Branding, Creative and Design, Digital Communications, Equitable access, Health policy and government affairs, Market Access, Medical Communications, Patient support and adherence, Sales, cell and gene therapy, clinical research, medical education, pharmacy, regulatory affairs
Isaac Batley, an experienced CEO with 35 years’ experience within healthcare and pharmaceutical communications, joins Uniphar to spearhead its medical communications division.
[Dublin 16th January 2025] Uniphar, a leading global partner to pharmaceutical and medtech manufacturers, announces the appointment of Isaac Batley as Global Head of Medical and Scientific Communications. In this pivotal role, Isaac will lead the growth of Uniphar’s medical communications capabilities, harnessing his 35 years of leadership experience working in healthcare communications within the pharmaceutical sector.
Isaac’s career includes serving as Chief Executive Officer at SCIRIS where he scaled the medical communications division globally, and heading-up the European Leadership Team at Cello Health before becoming Chairman of the communications agency. Prior to this, Isaac built and sold his own medical communications agency and held a Director-level role at Quintiles working specifically in clinical trials for the NHS.
Isaac spent the first part of his career working with AstraZeneca, Sanofi and Pfizer and his experience and expertise positions him to advance Uniphar’s medical communications, focusing on integrating scientific insights to benefit healthcare professionals, patients, and stakeholders.
Isaac will collaborate closely with key leaders across Uniphar, including Director of Medical Affairs, Maurice Leonard, Managing Director of Access, Dan Piggot, and Managing Director of Commercial, Karl Hamer, to ensure an integrated approach and cohesive medical communications strategy.
Commenting on his appointment, Isaac said: “Medical communications is the unifying thread that ties together the extensive service areas and capabilities that Uniphar has to offer. It touches every aspect of the organization and presents an exciting opportunity to bring these capabilities together in a way that delivers impactful and meaningful results. My remit will cover the whole organization, working to integrate and present Uniphar’s expertise in new and innovative ways.”
The appointment reinforces Uniphar’s ongoing commitment to bringing complex medicines to complex markets, and ensuring an expert team of industry leaders to deliver specialist services to more than 200 international clients across 180 countries.
“Isaac brings a unique perspective and extensive experience that aligns with our mission to transform patient access to medicines. As Uniphar continues to scale globally, Isaac’s leadership and strategic vision will be instrumental in supporting our continued development and growth,” says Brian O’Shaughnessy, Chief Commercial Officer at Uniphar.
For more information on Uniphar, visit www.Uniphar.com/Pharma
ENDS
For media enquiries, please contact:
Heather Hopkin at TALA at heather.hopkin@teamtala.com
Beth O’Shea at TALA at beth.oshea@teamtala.com
About Uniphar
Uniphar Group is a trusted global partner to pharma, medtech and biotech companies, working to improve patient access to medicines around the world. Uniphar’s team of experts harness the capabilities, infrastructure and expertise of a diversified pharmaceutical service provider with more than 55 years’ building success stories with 200+ multinational clients.
Our understanding of the shifting market dynamics allows us to deliver tailored specialist services and solutions for our clients’ changing needs. Uniphar Pharma comprises
Uniphar | Access, Uniphar | Medical, and Uniphar | Commercial – together our combined capabilities make us your trusted partner to unlock access for your patients to innovative therapies and optimize value for brands globally. Working from clinical development to commercialization, our end-to-end services remove barriers to launch, increase access and optimize brands.
This content was provided by Uniphar
Company Details
Latest Content from Uniphar
Uniphar announces U.S. expansion, integrating leading companies and appointing new senior leadership
- New integration aligns U.S. operations, unifying RRD BioPharma Development, Uniphar Clinical, Diligent Health Solutions and BESTMSLs under the Uniphar brand. - Mike Ebhardt is appointed President of Uniphar Pharma...
Uniphar On Track to Achieve SBTi Target of Halving Scope 1 and 2 Emissions by 2030
[Dublin, 9th October 2025] Uniphar, a global leader in pharmaceutical and medtech solutions, is making progress towards its near-term Science Based Targets initiative (SBTi) goal of halving Scope 1 and...
Streamlining European expansion for cell and gene therapies
Tom Smith, Strategic Director, Cell and Gene Therapies, Uniphar, discusses the essential elements biotechs need for commercial success in Europe’s unique market when developing cell and gene therapies (CGTs). Europe...
Current CGT landscape and future outlook
What makes CGT unique Cell and gene therapy (CGT) is a unique treatment that uses cells and genetic material to treat and cure diseases. Personalized to the patient, CGT’s offer...
Building for Success: Aligning Preclinical and Phase 1 Strategy with Commercial Goals
This article concludes our three-part series on preparing cell and gene therapies (CGTs) for successful launch and long-term viability. The first article explored the unique scientific and logistical challenges of...
Navigating the complexities of launch preparation for Cell and Gene Therapy
Cell and gene therapies (CGT) provide transformative treatment that can treat conditions that were previously considered untreatable. As described in the previous article in this series, most CGTs target patients...
Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries
Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia,...
Uniphar Rebrands On Demand Business to Uniphar Global Sourcing, Strengthening Global Pharmaceutical Offering
Dublin, Ireland 16th July 2025 – Leading global healthcare services provider, Uniphar, has launched Uniphar | Global Sourcing, a new identity for its On Demand business that strengthens its position...
Uniphar Secures 10th Cell and Gene Therapy Project
[Dublin, April 17th 2025] Uniphar, a global leader in pharmaceutical and medtech solutions has announced the launch of its 10th cell and gene therapy (CGT) project. The milestone reinforces Uniphar’s...
Uniphar Expands Global Footprint with Three New Facilities in the USA, Netherlands and Ireland
[Dublin, 05 February 2025] Global partner to pharmaceutical and medtech manufacturers, Uniphar, is expanding its international presence with the launch of three new, state-of-the-art facilities, strategically positioned across key global...
- 1
- 2